Expression Analysis of Two Cancer-testis Genes, FBXO39 and TDRD4, in Breast Cancer Tissues and Cell Lines

  • Seifi-Alan, Mahnaz (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Shamsi, Roshanak (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Ghafouri-Fard, Soudeh (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Mirfakhraie, Reza (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Zare-Abdollahi, Davood (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Movafagh, Abolfazl (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Modarressi, Mohammad Hossein (Department of Medical Genetics, Sina Hospital, Tehran University of Medical Sciences) ;
  • Kazemi, Golnesa (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) ;
  • Geranpayeh, Lobat (Department of Surgery, Sina Hospital, Tehran University of Medical Sciences) ;
  • Najafi-Ashtiani, Mitra (Shahid Madani Hospital)
  • Published : 2013.11.30


Breast cancer accounts for one third of new cancer cases among women. The need for biomarkers for early detection is the stimulus to researchers to evaluate altered expression of genes in tumours. Cancer-testis (CT) genes are a group with limited expression in normal tissues except testis but up-regulation in a wide variety of cancers. We here evaluated expression of two CT genes named FBXO39 and TDRD4 in 32 invasive ductal carcinoma samples, 10 fibroadenomas and 6 normal breast tissue samples, in addition to two breast cancer cell lines, MCF-7 and MDA-MB-231, by the means of quantitative real time RT-PCR. FBXO39 showed significant up-regulation in invasive ductal carcinoma samples in comparison with normal samples. It also was expressed in both cell lines and after RHOXF1 gene knock down it was down-regulated in MCF-7 but up-regulated in the MDA-MB-231 cell line. TDRD4 was not expressed in the MCF-7 cell line and any of the tissue samples except testis. However, it was expressed in MDA-MB-231 and was up-regulated after RHOXF1 gene knock down. Our results show that FBXO39 but not TDRD4 can be used for cancer detection and if proved to be immunogenic, might be a putative candidate for breast cancer immunotherapy.


Breast cancer;cell lines;cancer-testis genes;FBXO39;TDRD4


  1. Adams S, Greeder L, Reich E, et al (2011). Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother, 60, 999-1007.
  2. Bandi. D, Jureti. A, Sarcevi. B, et al (2006). Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J, 47, 32-41.
  3. Cenciarelli C, Chiaur DS, Guardavaccaro D, et al (1999). Identification of a family of human F-box proteins. Curr Biol, 9, 1177-9.
  4. Chen YT, Ross DS, Chiu R, et al (2011). Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One, 6, 17876.
  5. Cummings MC, Chambers R, Simpson PT, Lakhani SR (2011). Molecular classification of breast cancer: is it time to pack up our microscopes? Pathol, 43, 1-8.
  6. Curigliano G, Viale G, Ghioni M, et al (2010). Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol, 22, 98-103.
  7. Dianatpour M, Mehdipour P, Nayernia K, et al (2012). Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer. Iran Red Crescent Med J, 14, 722-6.
  8. Ghafouri-Fard S, Modarressi MH (2009). Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 12, 395-404.
  9. Ghafouri-Fard S, Modarressi MH (2012). Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunother, 4, 59-75.
  10. Ghafouri-Fard S, Abdollahi DZ, Omrani M, Azizi F (2012). shRNA mediated RHOXF1 silencing influences expression of Bcl-2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev, 13, 5865-9.
  11. Grigoriadis A, Caballero OL, Hoek KS, et al (2009). CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA, 106, 13493-8.
  12. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ (2004). Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev, 5, 24-7.
  13. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US--a SEER analysis. BMC Cancer, 10, 191.
  14. Mischo A, Kubuschok B, Ertan K, et al (2006). Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer, 118, 696-703.
  15. Mobasheri MB, Jahanzad I, Mohagheghi MA, et al (2007). Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev, 31, 296-302.
  16. Nakayama KI, Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer, 6, 369-81.
  17. Pan J, Goodheart M, Chuma S, et al (2005). RNF17, a component of the mammalian germ cell nuage, is essential for spermiogenesis. Development, 132, 4029-39.
  18. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  19. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. Ca Cancer J Clin, 63, 11-30.
  20. Song MH, Ha JC, Lee SM, Park YM, Lee SY (2011). Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun, 408, 195-201.
  21. Sun L, Shi L, Li W, et al (2009). JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci USA, 106, 10195-200.
  22. Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5947-54.
  23. Theurillat JP, Ingold F, Frei C, et al (2007). NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer, 120, 2411-7.
  24. Vahdaninia M, Montazeri A (2004). Survival rate of breast cancer. Asian Pac J Cancer Prev, 5, 223-5.
  25. Weigel RJ, deConinck EC (1993). Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res, 53, 3472-4.
  26. Yin XY, Grove LE, Prochownik EV (2001). Mmip-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones. Oncogene, 20, 2908-17.
  27. Yoon H, Lee H, Kim HJ, et al (2011). Tudor domain-containing protein 4 as a potential cancer/testis antigen in liver cancer. J Exp Med, 224, 41-6.
  28. Zheng Y, Rodrik V, Toschi A, et al (2006). Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem, 281, 15862-8.

Cited by

  1. Lactobacillus acidophilus and Lactobacillus crispatus Culture Supernatants Downregulate Expression of Cancer-testis Genes in the MDA-MB-231 Cell Line vol.15, pp.10, 2014,
  2. Expression analysis of four long noncoding RNAs in breast cancer vol.37, pp.3, 2016,
  3. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy vol.9, pp.12, 2017,
  4. Melanoma: a prototype of cancer-testis antigen-expressing malignancies vol.9, pp.13, 2017,
  5. Expression analysis of a panel of cancer-testis antigens in bladder cancer pp.1744-828X, 2018,
  6. Cancer testis antigens as immunogenic and oncogenic targets in breast cancer vol.10, pp.9, 2018,
  7. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma vol.10, pp.5, 2018,